Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | XPO1 | O14980 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026764 | 0.79 | HPGD (0.39) | HPGDUSP2SMN1; SMN2CTSKPREP | |
| SCHEMBL303433 | 0.78 | HPGD (0.41) | HPGDUSP2ALDH1A1MAPTNPC1 | |
| SCHEMBL6772333 | 0.77 | NFE2L2 (0.52) | HPGDUSP2ALDH1A1MAPTNPC1 | |
| SCHEMBL6772335 | 0.77 | NFE2L2 (0.52) | HPGDUSP2ALDH1A1MAPTNPC1 | |
| SCHEMBL4180059 | 0.75 | CTSK (0.41) | HPGDUSP2MAPTSMN1; SMN2CTSK | |
| SCHEMBL1144907 | 0.75 | NFE2L2 (0.50) | HPGDUSP2ALDH1A1MAPTNPC1 | |
| SCHEMBL1144905 | 0.75 | NFE2L2 (0.50) | HPGDUSP2ALDH1A1MAPTNPC1 | |
| SCHEMBL43004 | 0.75 | HCAR2 (0.45) | USP2ALDH1A1LMNASMN1; SMN2XPO1 | |
| SCHEMBL43764 | 0.75 | HCAR2 (0.45) | USP2ALDH1A1LMNASMN1; SMN2XPO1 | |
| SCHEMBL375029 | 0.75 | HCAR2 (0.45) | USP2ALDH1A1LMNASMN1; SMN2XPO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379511-B1 | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | HOFFMANN LA ROCHE (CH) | 2005-07-20 | — | — | EP | disclosed |
| US-6544985-B2 | For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits | HOFFMAN-LA ROCHE INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | CYP1B1, GRIN2B, BDKRB1 | HPGD 451/4885USP2 3528/4885ALDH1A1 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.